CoChat

Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial

Open access

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 (GLP-1) analogs are important therapeutics for type 2 diabetes and obesity. Ecnoglutide (XW003) is a novel, long-acting GLP-1 analog. We conducted a Phase 2, randomized, double-blind, placebo-controlled study enrolling 145 adults with T2DM. Participants were randomized to 0.4, 0.8, or 1.2 mg ecnoglutide or placebo as once-weekly injections for 20 weeks. The primary objective was to evaluate the efficacy of ecnoglutide, as measured by HbA1c change from baseline at Week 20. Secondary endpoints included body weight, glucose and lipid parameters, as well as safety. We show that, at end of treatment, the 0.4, 0.8, and 1.2 mg groups had statistically significant HbA1c reductions from baseline of −1.81%, −1.90%, and −2.39%, respectively, compared to −0.55% for placebo (P < 0.0001). At end of treatment, 71.9% of the 1.2 mg group had HbA1c ≤ 6.5% versus 9.1% on placebo, and 33.3% had body weight reductions ≥5% versus 3.0% for placebo. Ecnoglutide was generally safe and well tolerated. China Drug Trials Registry CTR20211014. A Phase 2, randomized, placebo-controlled study evaluated novel GLP-1 analog ecnoglutide in adults with type 2 diabetes. Here we show that ecnoglutide significantly reduced HbA1c from baseline up to -2.39% compared to -0.55% for placebo (P<0.0001), with a safety profile similar to approved GLP-1 analogs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-52353-y

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Participant disposition. Screening cases are defined as participants who signed the informed consent. Early withdrawal includes participants who withdrew prior to the end of study visit on Day 169.
Fig. 1 Participant disposition. Screening cases are defined as participants who signed the informed consent. Early withdrawal includes participants who withdrew prior to the end of study visit on Day 169.CC BY-NC-ND · PubMed Central
Fig. 2 HbA1c changes from baseline in participants treated with ecnoglutide or placebo. a HbA1c change from baseline to end of treatment (Day 134), derived from mixed model for repeated measures (MMRM) analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 36, 36, 36; Day 22, 36, 35, 35, 36; Day 50, 35, 34, 35, 36; Day 92, 35, 34, 33, 34; and Day 134, 33, 31, 32, 33. b HbA1c change from baseline at Day 134 and difference from placebo, derived from MMRM analysis, with n = 33, 31, 32, 33 participants in the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively. Least squares mean and SE are shown, as well as mean difference from placebo and 95% confidence interval. All ecnoglutide treatment groups were significantly different from placebo (P < 0.0001) using σ = 0.3 superiority margin. c, d The proportion of participants with HbA1c values of ≤6.5% and <7%, respectively, at Day 134. Intent to treat (ITT) population is shown for all analyses. BL baseline. Source data are provided as a Source Data file.
Fig. 2 HbA1c changes from baseline in participants treated with ecnoglutide or placebo. a HbA1c change from baseline to end of treatment (Day 134), derived from mixed model for repeated measures (MMRM) analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 36, 36, 36; Day 22, 36, 35, 35, 36; Day 50, 35, 34, 35, 36; Day 92, 35, 34, 33, 34; and Day 134, 33, 31, 32, 33. b HbA1c change from baseline at Day 134 and difference from placebo, derived from MMRM analysis, with n = 33, 31, 32, 33 participants in the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively. Least squares mean and SE are shown, as well as mean difference from placebo and 95% confidence interval. All ecnoglutide treatment groups were significantly different from placebo (P < 0.0001) using σ = 0.3 superiority margin. c, d The proportion of participants with HbA1c values of ≤6.5% and <7%, respectively, at Day 134. Intent to treat (ITT) population is shown for all analyses. BL baseline. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 3 Changes in glucose and glucagon from baseline. a Fasting blood glucose (FBG) change from baseline to end of treatment (Day 134), using mixed model for repeated measures (MMRM) analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 34, 34, 36; Day 22, 36, 35, 35, 36; Day 50, 35, 34, 35, 36; Day 92, 36, 34, 34, 36; and Day 134, 33, 31, 32, 34. P < 0.0001 for all ecnoglutide cohorts compared to placebo at Days 22, 50, 92, and 134. b Glucagon change from baseline to end of treatment (Day 134), using MMRM analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 36, 36, 36; Day 22, 36, 35, 35, 36; Day 50, 36, 35, 35, 36; Day 92, 36, 34, 34, 36; and Day 134, 34, 31, 32, 34. P < 0.0001 for ecnoglutide 1.2 mg compared to placebo at Day 92. P < 0.002 for ecnoglutide 0.4 and 0.8 mg on Day 92. P < 0.02 for ecnoglutide 1.2 mg on Day 134. c Self-monitored blood glucose pre- and post-meals at baseline and end of treatment (sampled between Days 135–140). Means and SE are shown. d SMBG average change from baseline to Week 20, derived from analysis of variance (one-way ANOVA). Least squares mean and SE are shown, as well as mean difference from placebo and 95% confidence interval. P values were 0.0002, 0.0002, and <0.0001, for 0.4, 0.8, 1.2 mg ecnoglutide compared to placebo, respectively. Numbers of participants (n) for SMBG for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are BL, 34, 35, 35, 34; Week 20, 29, 30, 28, 30. BL baseline. Source data are provided as a Source Data file.
Fig. 3 Changes in glucose and glucagon from baseline. a Fasting blood glucose (FBG) change from baseline to end of treatment (Day 134), using mixed model for repeated measures (MMRM) analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 34, 34, 36; Day 22, 36, 35, 35, 36; Day 50, 35, 34, 35, 36; Day 92, 36, 34, 34, 36; and Day 134, 33, 31, 32, 34. P < 0.0001 for all ecnoglutide cohorts compared to placebo at Days 22, 50, 92, and 134. b Glucagon change from baseline to end of treatment (Day 134), using MMRM analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 36, 36, 36; Day 22, 36, 35, 35, 36; Day 50, 36, 35, 35, 36; Day 92, 36, 34, 34, 36; and Day 134, 34, 31, 32, 34. P < 0.0001 for ecnoglutide 1.2 mg compared to placebo at Day 92. P < 0.002 for ecnoglutide 0.4 and 0.8 mg on Day 92. P < 0.02 for ecnoglutide 1.2 mg on Day 134. c Self-monitored blood glucose pre- and post-meals at baseline and end of treatment (sampled between Days 135–140). Means and SE are shown. d SMBG average change from baseline to Week 20, derived from analysis of variance (one-way ANOVA). Least squares mean and SE are shown, as well as mean difference from placebo and 95% confidence interval. P values were 0.0002, 0.0002, and <0.0001, for 0.4, 0.8, 1.2 mg ecnoglutide compared to placebo, respectively. Numbers of participants (n) for SMBG for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are BL, 34, 35, 35, 34; Week 20, 29, 30, 28, 30. BL baseline. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 4 Mean change in body weight from baseline. a Body weight change (kg) from baseline to end of treatment (Day 134), derived from mixed model for repeated measures (MMRM) analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 36, 36, 36; Day 8, 36, 36, 35, 36; Day 15, 36, 34, 35, 35; Day 22, 36, 35, 35, 36; Day 29, 36, 35, 33, 36; Day 36, 36, 33, 34, 36; Day 43, 35, 35, 35, 36; Day 50, 36, 34, 33, 36; Day 57, 36, 34, 33, 36; Day 64, 35, 34, 34, 32; Day 71, 35, 33, 32, 36; Day 78, 35, 33, 32, 34; Day 85, 35, 34, 33, 36; Day 92, 36, 34, 34, 34; Day 99, 35, 34, 33, 36; Day 106, 35, 33, 32, 34; Day 113, 36, 33, 33, 35; Day 120, 35, 33, 33, 35; Day 127, 35, 29, 33, 35; Day 134, 35, 34, 33, 33. P < 0.0001 for all ecnoglutide cohorts compared to placebo at Days 106, 120, 127, and 134. b Change in body weight compared to baseline (kg) and difference from placebo, derived from MMRM analysis. Least squares mean and SE are shown, with n = 35, 34, 33, 33 participants for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively. Mean difference from placebo and 95% confidence interval for mean difference are indicated. P < 0.0001 for all ecnoglutide cohorts compared to placebo. c Proportion of participants with body weight loss ≥5% from baseline at Day 134. BL baseline. Source data are provided as a Source Data file.
Fig. 4 Mean change in body weight from baseline. a Body weight change (kg) from baseline to end of treatment (Day 134), derived from mixed model for repeated measures (MMRM) analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 36, 36, 36; Day 8, 36, 36, 35, 36; Day 15, 36, 34, 35, 35; Day 22, 36, 35, 35, 36; Day 29, 36, 35, 33, 36; Day 36, 36, 33, 34, 36; Day 43, 35, 35, 35, 36; Day 50, 36, 34, 33, 36; Day 57, 36, 34, 33, 36; Day 64, 35, 34, 34, 32; Day 71, 35, 33, 32, 36; Day 78, 35, 33, 32, 34; Day 85, 35, 34, 33, 36; Day 92, 36, 34, 34, 34; Day 99, 35, 34, 33, 36; Day 106, 35, 33, 32, 34; Day 113, 36, 33, 33, 35; Day 120, 35, 33, 33, 35; Day 127, 35, 29, 33, 35; Day 134, 35, 34, 33, 33. P < 0.0001 for all ecnoglutide cohorts compared to placebo at Days 106, 120, 127, and 134. b Change in body weight compared to baseline (kg) and difference from placebo, derived from MMRM analysis. Least squares mean and SE are shown, with n = 35, 34, 33, 33 participants for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively. Mean difference from placebo and 95% confidence interval for mean difference are indicated. P < 0.0001 for all ecnoglutide cohorts compared to placebo. c Proportion of participants with body weight loss ≥5% from baseline at Day 134. BL baseline. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 5 Pharmacokinetics of ecnoglutide. a Linear and b semilog plots of ecnoglutide concentrations (ng/mL) over time. Mean and standard deviation (SD) are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide groups, respectively, are as follows: Day 1, 37, 36, 36; Day 22, 36, 35, 35; Day 50, 36, 34, 35; Day 92, 36, 34, 34; Day 134, 33, 31, 32; Day 137, 31, 28, 29; Day 148, 33, 28, 29; Day 169, 35, 34, 34. Source data are provided as a Source Data file.
Fig. 5 Pharmacokinetics of ecnoglutide. a Linear and b semilog plots of ecnoglutide concentrations (ng/mL) over time. Mean and standard deviation (SD) are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide groups, respectively, are as follows: Day 1, 37, 36, 36; Day 22, 36, 35, 35; Day 50, 36, 34, 35; Day 92, 36, 34, 34; Day 134, 33, 31, 32; Day 137, 31, 28, 29; Day 148, 33, 28, 29; Day 169, 35, 34, 34. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 1

  1. International Diabetes Federation. Diabetes prevalence. IDF Diabetes Atlas, 10th edition. 34–38 (2021)

Cited by

See all 34

Metadata

Authors
Zhu, D., Wang, W., Tong, G., Ma, G., Ma, J., Han, J., Zhang, X., Liu, Y., Gan, S., Qin, H., Zheng, Q., Ning, J., Zhu, Z., Guo, M., Bu, Y., Li, Y., Jones, C. L., Fenaux, M., Junaidi, M. K., Xu, S., & Pan, H.
Affiliations
  • Nanjing Drum Tower Hospital (CN)
  • Heilongjiang University of Chinese Medicine (CN)
  • Nanjing First Hospital (CN)
  • Daqing City People's Hospital (CN)
  • The First People's Hospital of Changde (CN)
Corresponding author
Zhu, Dalong
Venue
Nature Communications
Published
2024-09-27
Volume
15
Issue
1
Pages
8408-8408
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4402953901
Cited by
34
References
12
Citations by year
2026: 17 · 2025: 16 · 2024: 1
FWCI
11.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Sciwind Biosciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 analogues, type 2 diabetes, glycemic control, HbA1c reduction, weight loss, drug safety, long-acting insulin analogues
MeSH terms
Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. https://app.cochat.ai/papers/10.1038/s41467-024-52353-y
The paper
Zhu, D., Wang, W., Tong, G., Ma, G., Ma, J., Han, J., Zhang, X., Liu, Y., Gan, S., Qin, H., Zheng, Q., Ning, J., Zhu, Z., Guo, M., Bu, Y., Li, Y., Jones, C. L., Fenaux, M., Junaidi, M. K., . . . Pan, H. (2024). Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Communications. https://doi.org/10.1038/s41467-024-52353-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.